Exact Sciences Corporation (EXAS)
EXAS Stock Price Chart
Explore Exact Sciences Corporation interactive price chart. Choose custom timeframes to analyze EXAS price movements and trends.
EXAS Company Profile
Discover essential business fundamentals and corporate details for Exact Sciences Corporation (EXAS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
1 Feb 2001
Employees
6.90K
Website
https://www.exactsciences.comCEO
Kevin T. Conroy
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Financial Timeline
Browse a chronological timeline of Exact Sciences Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 17 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is $0.09.
Earnings released on 6 Aug 2025
EPS came in at $0.22 surpassing the estimated -$0.02 by +1.20K%, while revenue for the quarter reached $811.09M , beating expectations by +0.12%.
Earnings released on 1 May 2025
EPS came in at -$0.21 surpassing the estimated -$0.37 by +43.24%, while revenue for the quarter reached $706.79M , beating expectations by +2.64%.
Earnings released on 19 Feb 2025
EPS came in at -$0.06 surpassing the estimated -$0.29 by +79.31%, while revenue for the quarter reached $713.42M , beating expectations by +2.23%.
Earnings released on 5 Nov 2024
EPS came in at -$0.21 falling short of the estimated -$0.20 by -7.20%, while revenue for the quarter reached $708.66M , missing expectations by -1.14%.
Earnings released on 31 Jul 2024
EPS came in at -$0.09 surpassing the estimated -$0.37 by +75.68%, while revenue for the quarter reached $699.26M , beating expectations by +1.34%.
Earnings released on 8 May 2024
EPS came in at -$0.50 falling short of the estimated -$0.47 by -5.27%, while revenue for the quarter reached $637.52M , beating expectations by +1.62%.
Earnings released on 21 Feb 2024
EPS came in at -$0.27 surpassing the estimated -$0.53 by +49.06%, while revenue for the quarter reached $646.89M , beating expectations by +1.40%.
Earnings released on 1 Nov 2023
EPS came in at $0.00 surpassing the estimated -$0.48 by +100.90%, while revenue for the quarter reached $628.34M , beating expectations by +1.87%.
Earnings released on 1 Aug 2023
EPS came in at -$0.45 surpassing the estimated -$0.50 by +10.00%, while revenue for the quarter reached $622.09M , beating expectations by +3.66%.
Earnings released on 9 May 2023
EPS came in at -$0.42 surpassing the estimated -$0.79 by +46.84%, while revenue for the quarter reached $602.45M , beating expectations by +10.89%.
Earnings released on 21 Feb 2023
EPS came in at -$0.72 surpassing the estimated -$0.90 by +20.00%, while revenue for the quarter reached $553.00M , beating expectations by +4.89%.
Earnings released on 3 Nov 2022
EPS came in at -$0.84 surpassing the estimated -$1.10 by +23.64%, while revenue for the quarter reached $523.07M , beating expectations by +4.26%.
Earnings released on 2 Aug 2022
EPS came in at -$0.94 surpassing the estimated -$1.07 by +12.15%, while revenue for the quarter reached $521.64M , beating expectations by +4.54%.
Earnings released on 26 Apr 2022
EPS came in at -$1.04 surpassing the estimated -$1.12 by +7.14%, while revenue for the quarter reached $486.57M , beating expectations by +5.07%.
Earnings released on 22 Feb 2022
EPS came in at -$1.28 falling short of the estimated -$0.91 by -40.66%, while revenue for the quarter reached $473.81M , beating expectations by +5.50%.
Earnings released on 2 Nov 2021
EPS came in at -$0.97 falling short of the estimated -$0.89 by -8.99%, while revenue for the quarter reached $456.38M , beating expectations by +5.99%.
Earnings released on 28 Jul 2021
EPS came in at -$1.03 falling short of the estimated -$0.72 by -43.06%, while revenue for the quarter reached $434.82M , beating expectations by +0.98%.
Earnings released on 4 May 2021
EPS came in at -$0.18 surpassing the estimated -$1.04 by +82.69%, while revenue for the quarter reached $402.08M , beating expectations by +1.88%.
Earnings released on 16 Feb 2021
EPS came in at -$0.09 surpassing the estimated -$0.19 by +52.63%, while revenue for the quarter reached $466.34M , missing expectations by -89.60%.
Earnings released on 27 Oct 2020
EPS came in at -$0.36 surpassing the estimated -$0.51 by +29.41%, while revenue for the quarter reached $408.36M , beating expectations by +180.77%.
EXAS Stock Performance
Access detailed EXAS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.